Atlanta, GANCT07525843Now EnrollingIRB Ready

Patient-Reported Outcome Measures (PROMs) Clinical Trial in Atlanta, GA

Access cutting-edge patient-reported outcome measures (proms) treatment through this clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by Carelon Research

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access patient-reported outcome measures (proms) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related patient-reported outcome measures (proms) treatment provided free

Apply for This Atlanta Location

Check if you qualify for this patient-reported outcome measures (proms) clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Patient-Reported Outcome Measures (PROMs) Study in Atlanta

The goal of this pragmatic clinical trial is to learn if the WE BEAT program, a 5-week group-based online wellbeing and skill-building program, can help teens with congenital heart disease (CHD) improve their ability to handle stress. The main question it aims to answer is if participants who receive the WE BEAT program become more resilient (the ability to bounce back from from tough times or recover from something difficult) and have better quality of life compared to participants who receive usual care. The study also aims to learn if there are connections between participant-reported psychosocial data (such as resilience, feelings about one's life and one's physical, mental, and social wellbeing) and clinical outcomes. Eligible participants who are 12-17-year-old will be in the study for about 6 months and be randomized to receive either the WE BEAT program or usual care. Following completion of the primary WE BEAT intervention at Week 5, intervention arm participants will be randomized to a single-session booster session (occurring at Week 18) vs no booster session. The booster session will be provided in a similar format to the WE BEAT program. A review of all modules/skills introduced in the program will be provided. All participants will complete 4 sets of online surveys and give 3 hair/saliva samples at different timepoints. Some participants may volunteer to give optional blood and urine samples.

Sponsor: Carelon Research

Who Can Participate

Inclusion Criteria

Age 12-17 years old
CHD of moderate or severe complexity (Class II/III, 2018 AHA/ACC ACHD, Table 4)
English or Spanish language proficiency
Receives cardiology care at a PHN or PHN auxiliary site
Parent or guardian and participant willing to comply with protocol and provide written/electronic informed consent and assent

Exclusion Criteria

CHD of mild or simple complexity (Class I, 2018 AHA/ACC ACHD, Table 4)
Prior heart transplant to treat CHD
Heart disease that is not classified as structural CHD (e.g., connective tissue disease, genetic cardiomyopathy, or acquired heart disease)
Cognitive or developmental conditions that limit program participation and/or ability to complete self-reported measures as determined by a primary cardiology clinician
Suicidality, homicidality, or psychosis in the past 12 months as per medical chart review, clinician report, or eligibility screening
Medically unable to participate (e.g., intubated, unable to respond verbally, active delirium)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT07525843) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Patient-Reported Outcome Measures (PROMs) Treatment Options in Atlanta, GA

If you're searching for patient-reported outcome measures (proms) treatment options in Atlanta, GA, this clinical trial (NCT07525843) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced patient-reported outcome measures (proms) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all patient-reported outcome measures (proms) clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Atlanta, GA

See all multiple sclerosis clinical trials recruiting in Atlanta — not just this study.

Browse Multiple Sclerosis Trials in Atlanta

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA